[go: up one dir, main page]

WO1999036553A3 - Regulation of biological events using multimeric chimeric proteins - Google Patents

Regulation of biological events using multimeric chimeric proteins Download PDF

Info

Publication number
WO1999036553A3
WO1999036553A3 PCT/US1999/000178 US9900178W WO9936553A3 WO 1999036553 A3 WO1999036553 A3 WO 1999036553A3 US 9900178 W US9900178 W US 9900178W WO 9936553 A3 WO9936553 A3 WO 9936553A3
Authority
WO
WIPO (PCT)
Prior art keywords
regulation
biological events
chimeric proteins
multimeric chimeric
multimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/000178
Other languages
French (fr)
Other versions
WO1999036553A2 (en
Inventor
Timothy P Clackson
Michael Z Gilman
Dennis A Holt
Terence P Keenan
Leonard Rozamus
Wu Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ariad Gene Therapeutics Inc
Original Assignee
Ariad Gene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/012,097 external-priority patent/US6187757B1/en
Application filed by Ariad Gene Therapeutics Inc filed Critical Ariad Gene Therapeutics Inc
Priority to AU22132/99A priority Critical patent/AU755784B2/en
Priority to CA002318402A priority patent/CA2318402A1/en
Priority to JP2000540254A priority patent/JP2002508971A/en
Priority to EP99902059A priority patent/EP1045915A2/en
Publication of WO1999036553A2 publication Critical patent/WO1999036553A2/en
Publication of WO1999036553A3 publication Critical patent/WO1999036553A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Materials and methods are disclosed for regulation of biological events such as target gene transcription and growth, proliferation or differentiation of engineered cells.
PCT/US1999/000178 1998-01-15 1999-01-15 Regulation of biological events using multimeric chimeric proteins Ceased WO1999036553A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU22132/99A AU755784B2 (en) 1998-01-15 1999-01-15 Regulation of biological events using multimeric chimeric proteins
CA002318402A CA2318402A1 (en) 1998-01-15 1999-01-15 Regulation of biological events using multimeric chimeric proteins
JP2000540254A JP2002508971A (en) 1998-01-15 1999-01-15 Regulation of biological events using multimeric chimeric proteins
EP99902059A EP1045915A2 (en) 1998-01-15 1999-01-15 Regulation of biological events using multimeric chimeric proteins

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US7159198P 1998-01-15 1998-01-15
US7201698P 1998-01-21 1998-01-21
US7221998P 1998-01-22 1998-01-22
US09/012,097 1998-01-22
US60/071,591 1998-01-22
US09/012,097 US6187757B1 (en) 1995-06-07 1998-01-22 Regulation of biological events using novel compounds
US60/072,016 1998-01-22
US60/072,219 1998-01-22

Publications (2)

Publication Number Publication Date
WO1999036553A2 WO1999036553A2 (en) 1999-07-22
WO1999036553A3 true WO1999036553A3 (en) 1999-10-21

Family

ID=27486136

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/000178 Ceased WO1999036553A2 (en) 1998-01-15 1999-01-15 Regulation of biological events using multimeric chimeric proteins

Country Status (5)

Country Link
EP (1) EP1045915A2 (en)
JP (1) JP2002508971A (en)
AU (1) AU755784B2 (en)
CA (1) CA2318402A1 (en)
WO (1) WO1999036553A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426167B2 (en) 2001-06-22 2013-04-23 Roche Diagnostics Operations, Inc. Methods for producing fusion polypeptides or enhancing expression of fusion polypeptides

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69535829D1 (en) 1994-08-20 2008-10-16 Gendaq Ltd IMPROVEMENT RELATING TO BINDING PROTEINS IN THE DETECTION OF DNA
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6238884B1 (en) 1995-12-07 2001-05-29 Diversa Corporation End selection in directed evolution
US6939689B2 (en) 1995-12-07 2005-09-06 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US7018793B1 (en) 1995-12-07 2006-03-28 Diversa Corporation Combinatorial screening of mixed populations of organisms
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US6361974B1 (en) 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
US6479626B1 (en) 1998-03-02 2002-11-12 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
NZ506987A (en) 1998-03-17 2003-01-31 Sangamo Biosciences Inc Nucleic acid binding proteins
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US20030104526A1 (en) 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
CA2383451A1 (en) * 1999-08-24 2001-03-01 Ariad Gene Therapeutics, Inc. 28-epirapalogs
DE60023936T2 (en) 1999-12-06 2006-05-24 Sangamo Biosciences Inc., Richmond METHODS OF USING RANDOMIZED ZINCFINGER PROTEIN LIBRARIES FOR IDENTIFYING GENERAL FUNCTIONS
CA2398155C (en) 2000-01-24 2011-07-19 Sangamo Biosciences, Inc. Methods and compositions for linking binding domains in nucleic acid binding proteins
JP2004537260A (en) 2000-12-07 2004-12-16 サンガモ バイオサイエンシーズ， インコーポレイテッド Regulation of angiogenesis by zinc finger proteins
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
WO2002057293A2 (en) 2001-01-22 2002-07-25 Sangamo Biosciences, Inc. Modified zinc finger binding proteins
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
EA008379B1 (en) 2002-02-01 2007-04-27 Ариад Джин Терапьютикс, Инк. Phosphorus-containing compounds & uses thereof
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
US20080287675A1 (en) * 2007-05-18 2008-11-20 Abbott Laboratories Cascade system
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
BR112012024934A2 (en) 2010-03-29 2016-12-06 Univ Pennsylvania pharmacologically induced transgene ablation systems
US20140031418A1 (en) 2011-04-20 2014-01-30 The Trustees Of The University Of Pennsylvania Regimens and Compositions for AAV-Mediated Passive Immunization of Airborne Pathogens
SI3300745T1 (en) 2013-02-15 2020-01-31 The Regents Of The University Of California Chimeric antigen receptor and methods for their use
WO2015012924A2 (en) 2013-04-29 2015-01-29 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
DK3027204T3 (en) 2013-07-29 2022-04-19 2Seventy Bio Inc MULTIPLE SIGNAL PROTEINS AND USES THEREOF
EP3307310A2 (en) 2015-05-13 2018-04-18 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-influenza antibodies and methods of use thereof
US10392607B2 (en) 2015-06-03 2019-08-27 The Regents Of The University Of California Cas9 variants and methods of use thereof
EP3368054A4 (en) 2015-10-28 2019-07-03 Voyager Therapeutics, Inc. REGULATORY EXPRESSION USING AN ADENO-ASSOCIATED VIRUS (AAV)
WO2017087723A1 (en) 2015-11-19 2017-05-26 The Regents Of The University Of California Conditionally repressible immune cell receptors and methods of use thereof
JP2019506143A (en) * 2015-12-14 2019-03-07 ベリカム ファーマシューティカルズ， インコーポレイテッド Dual control for activation and elimination of therapeutic cells
WO2020047527A2 (en) 2018-09-02 2020-03-05 F1 Bioventures, Llc Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs
JP7046828B2 (en) 2016-04-15 2022-04-04 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Composition for the treatment of exudative age-related macular degeneration
CN118546256A (en) 2016-12-13 2024-08-27 西雅图儿童医院（Dba西雅图儿童研究所） Method for exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
JP7455579B2 (en) 2017-02-28 2024-03-26 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Novel adeno-associated virus (AAV) clade F vectors and their uses
SG11201907611WA (en) 2017-02-28 2019-09-27 Univ Pennsylvania Influenza vaccines based on aav vectors
JOP20190200A1 (en) 2017-02-28 2019-08-27 Univ Pennsylvania Compositions useful in treatment of spinal muscular atrophy
MX2019010445A (en) 2017-03-03 2019-10-24 F1 Oncology Inc METHODS AND COMPOSITIONS TO TRANSDUCE AND EXPAND LYMPHOCYTES AND REGULATE THE ACTIVITY OF THE SAME.
UY37900A (en) 2017-09-26 2019-04-30 Novartis Ag NEW DERIVATIVES OF RAPAMYCIN
WO2019079494A1 (en) 2017-10-18 2019-04-25 Regenxbio, Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap
MX2020003888A (en) 2017-10-18 2020-11-06 Regenxbio Inc Fully-human post-translationally modified antibody therapeutics.
WO2019118895A1 (en) 2017-12-14 2019-06-20 Bluebird Bio, Inc. Daric interleukin receptors
AU2019260687B2 (en) 2018-04-27 2022-09-22 Seattle Children's Hospital (dba Seattle Children's Research Institute) Rapamycin resistant cells
IL312291A (en) 2018-05-01 2024-06-01 Revolution Medicines Inc C26-linked rapamycin analogs as mtor inhibitors
TW202438112A (en) 2018-05-01 2024-10-01 美商銳新醫藥公司 C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
CA3112310A1 (en) 2018-10-05 2020-04-09 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
US20210386781A1 (en) 2018-10-05 2021-12-16 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
EP3632461A1 (en) 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
EP3632460A1 (en) 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
US12291560B2 (en) 2018-12-14 2025-05-06 Regeneron Pharmaceuticals, Inc. Dimerizing agent regulated immunoreceptor complexes
MX2021007247A (en) * 2018-12-18 2021-07-15 Novartis Ag Rapamycin derivatives.
AU2020253462A1 (en) 2019-04-03 2021-10-28 Regenxbio Inc. Gene therapy for eye pathologies
US20220195462A1 (en) 2019-04-24 2022-06-23 Regenxbio Inc. Fully-human post-translationally modified antibody therapeutics
EP3966243A1 (en) 2019-05-04 2022-03-16 Inhibrx, Inc. Clec12a-binding polypeptides and uses thereof
MA55905A (en) 2019-05-08 2022-03-16 2Seventy Bio Inc IMMUNOTHERAPIES TARGETING CLL -1
MX2022002366A (en) 2019-08-26 2022-07-19 Regenxbio Inc Treatment of diabetic retinopathy with fully-human post-translationally modified anti-vegf fab.
EP4041292A1 (en) 2019-10-07 2022-08-17 RegenxBio Inc. Adeno-associated virus vector pharmaceutical composition and methods
KR20220128345A (en) * 2019-12-05 2022-09-20 아나쿠리아 테라퓨틱스, 인코포레이티드 Rapamycin analogs and uses thereof
CN119954829A (en) * 2020-03-27 2025-05-09 艾奥维安制药公司 MTORC1 modulators and uses thereof
US20250326861A1 (en) 2020-09-15 2025-10-23 Regenxbio Inc. Vectorized lanadelumab and administration thereof
WO2022060916A1 (en) 2020-09-15 2022-03-24 Regenxbio Inc. Vectorized antibodies for anti-viral therapy
US20230364206A1 (en) 2020-10-07 2023-11-16 Regenxbio Inc. Gene therapy for ocular manifestations of cln2 disease
AR123948A1 (en) 2020-10-28 2023-01-25 Regenxbio Inc VECTORIZED ANTI-TNF-α ANTIBODIES FOR OCULAR INDICATIONS
WO2022094157A1 (en) 2020-10-28 2022-05-05 Regenxbio Inc. Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
EP4237453A1 (en) 2020-10-29 2023-09-06 RegenxBio Inc. Vectorized tnf-alpha antagonists for ocular indications
WO2022094255A2 (en) 2020-10-29 2022-05-05 Regenxbio Inc. Vectorized factor xii antibodies and administration thereof
AU2021390480A1 (en) 2020-12-01 2023-06-22 The Trustees Of The University Of Pennsylvania Novel compositions with tissue-specific targeting motifs and compositions containing same
WO2022187289A1 (en) 2021-03-01 2022-09-09 Exuma Biotech Corp. Methods and compositions for the delivery of retroviral particles
AU2022262771A1 (en) 2021-04-23 2023-11-02 The Trustees Of The University Of Pennsylvania Novel compositions with brain-specific targeting motifs and compositions containing same
TW202325845A (en) 2021-10-02 2023-07-01 賓州大學委員會 Novel aav capsids and compositions containing same
MX2024009186A (en) 2022-01-25 2024-09-30 Univ Pennsylvania AAV CAPSIDS FOR IMPROVING CARDIAC TRANSDUCTION AND LIVER DETARGETING.
EP4469586A1 (en) 2022-03-01 2024-12-04 Exuma Biotech Corp. Viral particles with membrane-bound hyaluronidase
US20250249127A1 (en) 2022-04-14 2025-08-07 Regenxbio Inc. Gene therapy for treating an ocular disease
US20250277004A1 (en) 2022-04-18 2025-09-04 Regenxbio Inc. Hybrid aav capsids
US20250288697A1 (en) 2022-05-03 2025-09-18 Regenxbio Inc. Vectorized anti-tnf-alpha inhibitors for ocular indications
AR129215A1 (en) 2022-05-03 2024-07-31 Regenxbio Inc ANTI-COMPLEMENT ANTIBODIES AND VECTORIZED COMPLEMENT AGENTS AND THEIR ADMINISTRATION
JP2025522296A (en) 2022-05-25 2025-07-15 レヴォリューション・メディスンズ，インコーポレイテッド Methods of Treating Cancer with mTOR Inhibitors
IL319873A (en) 2022-09-30 2025-05-01 Regenxbio Inc Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab
AU2023398931A1 (en) 2022-12-17 2025-07-10 The Trustees Of The University Of Pennsylvania Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same
WO2024130070A2 (en) 2022-12-17 2024-06-20 The Trustees Of The University Of Pennsylvania Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
WO2024238859A1 (en) 2023-05-16 2024-11-21 Regenxbio Inc. Vectorized c5 inhibitor agents and administration thereof
WO2024238867A1 (en) 2023-05-16 2024-11-21 Regenxbio Inc. Vectorized anti-complement antibodies and administration thereof
WO2025007046A1 (en) 2023-06-29 2025-01-02 The Trustees Of The University Of Pennsylvania Mutant aav with central nervous system targeting motifs and compositions containing same
WO2025102034A1 (en) 2023-11-10 2025-05-15 The Trustees Of The University Of Pennsylvania Gene therapy for barth syndrome
WO2025106661A1 (en) 2023-11-14 2025-05-22 The Trustees Of The University Of Pennsylvania Compositions with cardiac and skeletal musclespecific targeting motifs and uses thereof
WO2025217230A1 (en) 2024-04-08 2025-10-16 Regenxbio Inc. Vectorized anti-complement antibodies and complement agents and administration thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
WO1996041865A1 (en) * 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamcycin-based regulation of biological events

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
WO1996041865A1 (en) * 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamcycin-based regulation of biological events

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JUAN I LUENGO ET AL.: "Structure-activity studies of rapamycin analogs: evidence that the C-7 methoxy group is part of the effector domainand positioned at the FKBP12-FRAP interface", CURRENT BIOLOGY, vol. 2, 1995, pages 471 - 481, XP002045681 *
VICTOR M. RIVERA ET AL.: "A humanized system for phamacologic control of gene expression", NATURE MEDICINE, vol. 2, no. 9, September 1996 (1996-09-01), pages 1028 - 1032, XP002018162 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8426167B2 (en) 2001-06-22 2013-04-23 Roche Diagnostics Operations, Inc. Methods for producing fusion polypeptides or enhancing expression of fusion polypeptides

Also Published As

Publication number Publication date
CA2318402A1 (en) 1999-07-22
AU755784B2 (en) 2002-12-19
WO1999036553A2 (en) 1999-07-22
AU2213299A (en) 1999-08-02
EP1045915A2 (en) 2000-10-25
JP2002508971A (en) 2002-03-26

Similar Documents

Publication Publication Date Title
WO1999036553A3 (en) Regulation of biological events using multimeric chimeric proteins
IL206293A0 (en) Genetically engineered duckweed
CA2383926A1 (en) Functional genomics using zinc finger proteins
WO2002059277A3 (en) Electroactive materials for stimulation of biological activity of stem cells
AU560340B2 (en) Rennin from recombinant dna
WO2003016511A1 (en) Method of extended culture for antigen-specific cytotoxic t lumphocytes
AU2002235994A1 (en) Method for producing proteins by fermentation of microorganisms from the thermus family, the protein mixture thus obtained and cosmetic compositions containing same
AU3462899A (en) Sequence and method for genetic engineering of proteins with cell membrane translocating activity
AU6724194A (en) Nucleotide sequences for the control of the expression of dna sequences in a cellular host
AU7926098A (en) Methods and means for control of flowering in plants
WO2004044183A3 (en) Feeding processes for fermentation
AU2028601A (en) Arginine-enriched medium composition used for mass-producing recombinant proteinin animal cell culture
DE69830066D1 (en) Lunasin peptide
WO2004010925A3 (en) Mammalian genes involved in viral infection and tumor suppression
WO2000029551A3 (en) Cells, culture methods, and their use in autologous transplantation therapy
CA2219962A1 (en) C3 plants expressing photosynthetic enzyme of c4 plants
WO2000004051A3 (en) Growth differentiation factor promoter and uses therefor
WO2002002591A3 (en) Peptides for use in culture media
GB9901499D0 (en) Biological control
AU2001278700A1 (en) Method of culturing human chondrocytes
WO2000006713A3 (en) Methods for recombinant protein production in mammalian cells comprising co-expression with fetuin
AU2342899A (en) Method of screening for neuropharmaceuticals using the (drosophila) gene (volado) and its mutants
CA2375549A1 (en) Delivery system for biological material
EP1728859A4 (en) Sequence capable of accelerating gene expression at moderately low temperature
WO2001040443A3 (en) Method for producing adherent animal cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2318402

Country of ref document: CA

Ref country code: CA

Ref document number: 2318402

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 540254

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 22132/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999902059

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09600241

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999902059

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 22132/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999902059

Country of ref document: EP